百利達(08179.HK)獲主席配偶注入口罩生產線50.77%股權
百利達(08179.HK)公布,以3,285萬元向主席黃巍配偶收購目標公司50.77%股權,代價將以900萬元現金,及發行股份支付。
股份發行價為0.225元,,較上一交易日折讓2.6%,涉及1.06億股。賣方將提供今年不低於1,000萬元之溢利保證。
目標公司主要業務為即棄式口罩之出售、製造、分銷及批發。目前,目標公司在香港經營一家生產工廠,並已成功建立20條生產線以生產即棄式口罩。目標公司的口罩產品已獲得ASTM 3級證書及其他國際品質標準證書。即棄式口罩通過批發分銷、零售和網店等多種渠道銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.